BLC
MCID: BLD134
MIFTS: 71

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Cancer

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 58 12 54 26 76 38 56 44 15 39
Bladder Carcinoma 39 12 30 56 6 15 17
Bladder Cancer, Somatic 58 30 13 6
Urinary Bladder Cancer 12 26 76 15
Malignant Neoplasm of Urinary Bladder 74
Urothelial Carcinoma of the Bladder 76
Malignant Tumor of Urinary Bladder 26
Carcinoma of Urinary Bladder 12
Urinary Bladder Neoplasms 45
Cancer of the Bladder 26
Tumor of the Bladder 12
Carcinoma of Bladder 74
Bladder Neoplasm 74
Cancer, Bladder 41
Bladder Tumors 56
Bladder Tumor 17
Blc 76

Characteristics:

OMIM:

58
Inheritance:
somatic mutation


HPO:

33
bladder cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11054 DOID:4007
OMIM 58 109800
KEGG 38 H00022
ICD9CM 36 188 188.9
MeSH 45 D001749
SNOMED-CT 69 93689003
ICD10 34 C67 C67.9
MedGen 43 C0005684
SNOMED-CT via HPO 70 255109008 263681008

Summaries for Bladder Cancer

MedlinePlus : 44 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Bladder Cancer, also known as bladder carcinoma, is related to transitional cell carcinoma and bladder adenocarcinoma. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Bladder cancer and MicroRNAs in cancer. The drugs Valstar and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and lymph node, and related phenotype is transitional cell carcinoma of the bladder.

Disease Ontology : 12 An urinary system cancer that results in malignant growth located in the urinary bladder.

Genetics Home Reference : 26 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

NIH Rare Diseases : 54 Bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. Signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. Most cases of bladder cancer occur sporadically in people with no family history of the condition. Risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. Treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy.

UniProtKB/Swiss-Prot : 76 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Wikipedia : 77 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is... more...

Description from OMIM: 109800

Related Diseases for Bladder Cancer

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 33.0 BRINP1 FGFR3 HRAS
2 bladder adenocarcinoma 32.3 HRAS UCA1
3 prostate cancer 31.4 KRAS HRAS H19 GAS5 MIR10B MIR127
4 bladder urothelial carcinoma 31.3 FGFR3 GAS5 HRAS KRAS RB1 TUG1
5 renal cell carcinoma, nonpapillary 31.1 GAS5 H19 TSC1 TUG1 UCA1
6 adenocarcinoma 31.1 FGFR3 H19 HRAS KRAS RB1
7 lung cancer 31.1 ZEB2-AS1 UCA1 TUG1 RB1 MIR221 MIR21
8 squamous cell carcinoma 31.1 FGFR3 H19 HRAS RB1 TUG1 UCA1
9 breast cancer 30.8 GAS5 H19 HRAS KRAS MIR10B MIR127
10 gallbladder cancer 30.7 H19 KRAS TUG1 UCA1
11 melanoma 30.6 GAS5 H19 MIR127 MIR221 UCA1
12 kidney cancer 30.6 GAS5 H19 MIR21
13 nevus, epidermal 30.5 FGFR3 HRAS KRAS
14 myeloma, multiple 30.5 FGFR3 GAS5 H19 HRAS KRAS TUG1
15 leukemia, chronic lymphocytic 2 30.5 HRAS KRAS MIR143
16 lung cancer susceptibility 3 30.5 BLACAT1 FGFR3 GAS5 H19 HRAS KRAS
17 colorectal cancer 30.5 UCA1 TUG1 MIR221 MIR21 MIR143 MIR127
18 cervical cancer 30.5 MIR143 HRAS H19 GAS5 FGFR3 BLACAT1
19 endometrial cancer 30.4 GAS5 H19 HRAS KRAS RB1 TUG1
20 cholangiocarcinoma 30.4 H19 KRAS MIR21 TUG1 UCA1
21 gastric cancer 30.4 BLACAT1 GAS5 GHET1 H19 KRAS MIR143
22 intrahepatic cholangiocarcinoma 30.3 KRAS MIR127 TUG1
23 glioblastoma 30.3 GAS5 H19 HRAS MIR10B MIR21 MIR221
24 polymyositis 30.3 MIR127 MIR21
25 ovarian cancer 30.2 GAS5 H19 KRAS MIR10B MIR127 MIR143
26 small cell cancer of the lung 29.8 MIR21 RB1 TUG1
27 superficial urinary bladder cancer 12.3
28 jewett-marshall bladder cancer 12.1
29 bladder cancer, childhood 12.1
30 gall bladder carcinoma in situ 12.0
31 small cell carcinoma of the bladder 12.0
32 chondrodysplasia, blomstrand type 11.8
33 midline interhemispheric variant of holoprosencephaly 11.4
34 schistosomiasis 11.4
35 urinary bladder small cell neuroendocrine carcinoma 11.3
36 urinary schistosomiasis 11.3
37 urachal cancer 11.1
38 pseudo-torch syndrome 1 11.1
39 congenital intrauterine infection-like syndrome 11.1
40 bladder squamous cell carcinoma 11.1
41 danubian endemic familial nephropathy 10.9
42 bladder disease 10.9
43 neuroschistosomiasis 10.9
44 adenosquamous lung carcinoma 10.7 FGFR3 HRAS KRAS
45 sigmoid neoplasm 10.7 HRAS KRAS
46 lung squamous cell carcinoma 10.7 FGFR3 HRAS KRAS TUG1
47 apocrine adenoma 10.7 HRAS KRAS
48 periampullary adenoma 10.7 HRAS KRAS
49 esophageal cancer 10.6 GAS5 H19 HRAS KRAS MIR21 RB1
50 leukemia, acute myeloid 10.6 HRAS KRAS MIR21 MIR221 TUG1 UCA1

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Ischemic Heart Disease
Neutropenia Paralytic Ileus
Prostate Cancer Prostatic Hypertrophy
Radiation Cystitis Renal Pelvis Carcinoma
Ureter, Cancer of Urethral Benign Neoplasm
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer

Symptoms & Phenotypes for Bladder Cancer

Human phenotypes related to Bladder Cancer:

33
# Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 33 HP:0006740

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
bladder cancer
transitional cell bladder carcinoma

Clinical features from OMIM:

109800

Drugs & Therapeutics for Bladder Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Valstar 19 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 536)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
3
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 441203 84093 2767
5
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
6
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
7
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
8
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
9
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
12
Benzocaine Approved, Investigational Phase 4,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
13
tannic acid Approved Phase 4,Phase 2,Not Applicable 1401-55-4
14
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
15
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
16
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
17
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
18
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
19
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
22
Parecoxib Approved Phase 4 198470-84-7
23
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
24
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
25
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
26
Alverine Approved, Investigational Phase 4 150-59-4 3678
27
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
28
Alogliptin Approved Phase 4 850649-61-5 11450633
29
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
30
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
31
BCG vaccine Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
33
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
34
Fibrinolysin Investigational Phase 4 9004-09-5
35 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Analgesics, Opioid Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
39 Narcotics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hypnotics and Sedatives Phase 4,Not Applicable
42 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1111)
# Name Status NCT ID Phase Drugs
1 The Assessment of POCD After TURBT Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
2 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
3 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4 Tamsulosin
4 Sequential Combination Therapy in Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
5 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
6 Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer Completed NCT02214602 Phase 4 Epirubicin
7 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
8 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer Not yet recruiting NCT03274284 Phase 4
9 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
10 "En Bloc" Resection of NMIBC: a Prospective, Single Centre,Randomized Study Not yet recruiting NCT03221062 Phase 4
11 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
12 Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach Recruiting NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
13 Investigation of Sugammadex in Outpatient Urological Procedures Recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
14 Peri-operative Aspirin Continuation Versus Discontinuation Enrolling by invitation NCT02350543 Phase 4 Aspirin
15 Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? Active, not recruiting NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
16 Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology Completed NCT02653261 Phase 4 Tranexamic Acid;Placebo
17 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Withdrawn NCT02734186 Phase 4 Praziquantel
18 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy Active, not recruiting NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
19 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
20 Parecoxib for Treatment of Catheter Related Bladder Discomfort Completed NCT02729935 Phase 4 Parecoxib;Placebo
21 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Recruiting NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
22 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
23 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
24 Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners Recruiting NCT03652298 Phase 4
25 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders Recruiting NCT03147599 Phase 4 Coloverin;Placebo
26 The Practical Evidence of Antidiabetic Combination Therapy in Korea Completed NCT02231021 Phase 4 alogliptin;Pioglitazone;alogliptin + pioglitazone
27 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
28 Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor Unknown status NCT01581723 Phase 3
29 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
30 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
31 Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer Unknown status NCT02074189 Phase 3 Gemcitabine, Cisplatin
32 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
33 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
34 Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection Unknown status NCT00816075 Phase 2, Phase 3 distilled water
35 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
36 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
37 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
38 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
39 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
40 The Bladder Instillation Comparison Study Unknown status NCT02695771 Phase 3 Mitomycin C;Gemcitabine
41 Tranexamic Acid During Cystectomy Trial (TACT) Unknown status NCT01869413 Phase 2, Phase 3 Tranexamic Acid;Placebo
42 Efficacy of Diclofenac BCG Irrigations Unknown status NCT01542567 Phase 3 Abitren;Placebo
43 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
44 Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) Recruiting NCT01675219 Phase 3 optimized MMC;single immediate chemotherapy instillation
45 Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer Not yet recruiting NCT03664869 Phase 3 BCG instillation therapy;Sequential BCG and EMDA mitomycin C
46 Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer Recruiting NCT03298958 Phase 3 Rapamycin;Placebo Oral Tablet
47 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
48 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
49 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) Completed NCT00598806 Phase 3 Apaziquone;Placebo
50 Assessment of BladderLight SurvEILlance Not yet recruiting NCT03427034 Phase 2, Phase 3

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit�, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit� PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Bladder Cancer

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Bladder Cancer, Somatic 30 FGFR3 HRAS KRAS RB1
2 Bladder Carcinoma 30

Anatomical Context for Bladder Cancer

MalaCards organs/tissues related to Bladder Cancer:

42
Prostate, Testes, Lymph Node, Lung, T Cells, Kidney, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Cancer:

20
The Urinary Bladder

Publications for Bladder Cancer

Articles related to Bladder Cancer:

(show top 50) (show all 8251)
# Title Authors Year
1
Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis. ( 30387807 )
2019
2
Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis. ( 30881921 )
2019
3
CARLo-7-A plausible biomarker for bladder cancer. ( 30883984 )
2019
4
Synergistic effect of phototherapy and chemotherapy on bladder cancer cells. ( 30884284 )
2019
5
MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer. ( 30885775 )
2019
6
Identification of a nine-gene panel as a prognostic indicator for recurrence with muscle-invasive bladder cancer. ( 30887516 )
2019
7
Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. ( 30888482 )
2019
8
The interaction of gender and smoking on bladder cancer risks. ( 30888973 )
2019
9
CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer. ( 30890547 )
2019
10
Urinary bladder cancer in Jordanian adults: A histopathological and epidemiological study from a tertiary care center in Amman. ( 30890838 )
2019
11
Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments. ( 30893148 )
2019
12
En-bloc resection of non-muscle invasive bladder cancer: what must be answered in the future? ( 30895361 )
2019
13
MicroRNA‑663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2. ( 30896880 )
2019
14
miR-3622a promotes proliferation and invasion of bladder cancer cells by downregulating LASS2. ( 30898713 )
2019
15
Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer. ( 30900154 )
2019
16
Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer. ( 30901172 )
2019
17
LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase (GLS) expression. ( 30902882 )
2019
18
Patients choose certainty over burden in bladder cancer surveillance. ( 30903352 )
2019
19
Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer. ( 30903422 )
2019
20
Flavonoids and bladder cancer risk. ( 30903485 )
2019
21
Hope and challenge: Precision medicine in bladder cancer. ( 30907072 )
2019
22
Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression. ( 30909190 )
2019
23
Influence of laparoscopic access in cancer-specific mortality of patients with pTa-2pN0R0 bladder cancer treated with radical cistectomy. ( 30910257 )
2019
24
Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.040: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer. ( 30910345 )
2019
25
Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment. ( 30911586 )
2019
26
Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection. ( 30911812 )
2019
27
PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells. ( 30912275 )
2019
28
Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer. ( 30914736 )
2019
29
Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis. ( 30914794 )
2019
30
MicroRNA-338-3p inhibits the progression of bladder cancer through regulating ETS1 expression. ( 30915741 )
2019
31
Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan. ( 30916420 )
2019
32
lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. ( 30916832 )
2019
33
Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy? ( 30806186 )
2019
34
Vitamin E consumption and the risk of bladder cancer. ( 30806606 )
2019
35
Association of body mass index with bladder cancer risk in men depends on abdominal obesity. ( 30806768 )
2019
36
Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. ( 30806832 )
2019
37
Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). ( 30806902 )
2019
38
Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer. ( 30808674 )
2019
39
Synthesis and characterization of gold nanoparticles from Abies spectabilis extract and its anticancer activity on bladder cancer T24 cells. ( 30810403 )
2019
40
Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice? ( 30811286 )
2019
41
Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. ( 30811419 )
2019
42
Selective Tetramodal Bladder Preservation Therapy Incorporating Induction Chemoradiotherapy and Consolidative Partial Cystectomy with Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: Oncological and Functional Outcomes of 107 Patients. ( 30811784 )
2019
43
Proteomics Analysis of Tangeretin-Induced Apoptosis through Mitochondrial Dysfunction in Bladder Cancer Cells. ( 30813616 )
2019
44
Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. ( 30815670 )
2019
45
Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. ( 30816487 )
2019
46
Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway. ( 30816494 )
2019
47
Chlorophyllin e6‑mediated photodynamic therapy inhibits proliferation and induces apoptosis in human bladder cancer cells. ( 30816498 )
2019
48
Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. ( 30819527 )
2019
49
The RING domain in the anti-apoptotic protein XIAP stabilizes c-Myc protein and preserves anchorage-independent growth of bladder cancer cells. ( 30819803 )
2019
50
Application of the Z-scan technique for the detection of CFCDNA (cell-free circulating DNA) and urine DNA (uDNA) in patients with bladder cancer. ( 30822568 )
2019

Variations for Bladder Cancer

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

76
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

ClinVar genetic disease variations for Bladder Cancer:

6 (show top 50) (show all 133)
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
3 RB1 RB1, IVS20, A-G, -2 single nucleotide variant Pathogenic
4 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic rs121913484 GRCh37 Chromosome 4, 1806092: 1806092
5 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic rs121913484 GRCh38 Chromosome 4, 1804365: 1804365
6 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
7 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
8 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
9 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 GRCh38 Chromosome 4, 1804372: 1804372
10 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
11 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 GRCh38 Chromosome 4, 1806162: 1806162
12 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 GRCh37 Chromosome 4, 1806089: 1806089
13 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 GRCh38 Chromosome 4, 1804362: 1804362
14 FGFR3 NM_001163213.1(FGFR3): c.2095G> T (p.Gly699Cys) single nucleotide variant Likely pathogenic rs121913480 GRCh38 Chromosome 4, 1806604: 1806604
15 FGFR3 NM_001163213.1(FGFR3): c.2095G> T (p.Gly699Cys) single nucleotide variant Likely pathogenic rs121913480 GRCh37 Chromosome 4, 1808331: 1808331
16 MRE11 NM_005590.3(MRE11): c.1563+281G> A single nucleotide variant other rs397509429 GRCh38 Chromosome 11, 94455995: 94455995
17 MRE11 NM_005590.3(MRE11): c.1563+281G> A single nucleotide variant other rs397509429 GRCh37 Chromosome 11, 94189161: 94189161
18 MRE11 NM_005590.3(MRE11): c.545-297G> T single nucleotide variant other rs118024137 GRCh38 Chromosome 11, 94476700: 94476700
19 MRE11 NM_005590.3(MRE11): c.545-297G> T single nucleotide variant other rs118024137 GRCh37 Chromosome 11, 94209866: 94209866
20 MRE11 NM_005590.3(MRE11): c.314+99A> G single nucleotide variant other rs143677623 GRCh38 Chromosome 11, 94485825: 94485825
21 MRE11 NM_005590.3(MRE11): c.314+99A> G single nucleotide variant other rs143677623 GRCh37 Chromosome 11, 94218991: 94218991
22 MRE11 NM_005590.3(MRE11): c.20+821G> A single nucleotide variant other rs397509351 GRCh38 Chromosome 11, 94491961: 94491961
23 MRE11 NM_005590.3(MRE11): c.20+821G> A single nucleotide variant other rs397509351 GRCh37 Chromosome 11, 94225127: 94225127
24 MRE11 NM_005590.3(MRE11): c.1783+888A> G single nucleotide variant other rs397509358 GRCh38 Chromosome 11, 94446331: 94446331
25 MRE11 NM_005590.3(MRE11): c.1783+888A> G single nucleotide variant other rs397509358 GRCh37 Chromosome 11, 94179497: 94179497
26 MRE11 NM_005590.3(MRE11): c.1783+561G> A single nucleotide variant other rs397509357 GRCh38 Chromosome 11, 94446658: 94446658
27 MRE11 NM_005590.3(MRE11): c.1783+561G> A single nucleotide variant other rs397509357 GRCh37 Chromosome 11, 94179824: 94179824
28 MRE11 NM_005590.3(MRE11): c.1327-461A> C single nucleotide variant other rs185485357 GRCh38 Chromosome 11, 94460042: 94460042
29 MRE11 NM_005590.3(MRE11): c.1327-461A> C single nucleotide variant other rs185485357 GRCh37 Chromosome 11, 94193208: 94193208
30 MRE11 NM_005590.3(MRE11): c.1225+804T> C single nucleotide variant other rs397509356 GRCh38 Chromosome 11, 94463309: 94463309
31 MRE11 NM_005590.3(MRE11): c.1225+804T> C single nucleotide variant other rs397509356 GRCh37 Chromosome 11, 94196475: 94196475
32 MRE11 NM_005590.3(MRE11): c.1225+605T> C single nucleotide variant other rs397509355 GRCh38 Chromosome 11, 94463508: 94463508
33 MRE11 NM_005590.3(MRE11): c.1225+605T> C single nucleotide variant other rs397509355 GRCh37 Chromosome 11, 94196674: 94196674
34 MRE11 NM_005590.3(MRE11): c.1225+577A> C single nucleotide variant other rs397509354 GRCh38 Chromosome 11, 94463536: 94463536
35 MRE11 NM_005590.3(MRE11): c.1225+577A> C single nucleotide variant other rs397509354 GRCh37 Chromosome 11, 94196702: 94196702
36 MRE11 NM_005590.3(MRE11): c.1225+572A> T single nucleotide variant other rs397509353 GRCh38 Chromosome 11, 94463541: 94463541
37 MRE11 NM_005590.3(MRE11): c.1225+572A> T single nucleotide variant other rs397509353 GRCh37 Chromosome 11, 94196707: 94196707
38 MRE11 NM_005590.3(MRE11): c.1225+40T> C single nucleotide variant other rs192979170 GRCh38 Chromosome 11, 94464073: 94464073
39 MRE11 NM_005590.3(MRE11): c.1225+40T> C single nucleotide variant other rs192979170 GRCh37 Chromosome 11, 94197239: 94197239
40 MRE11 NM_005590.3(MRE11): c.1202A> G (p.His401Arg) single nucleotide variant Uncertain significance rs146779325 GRCh38 Chromosome 11, 94464136: 94464136
41 MRE11 NM_005590.3(MRE11): c.1202A> G (p.His401Arg) single nucleotide variant Uncertain significance rs146779325 GRCh37 Chromosome 11, 94197302: 94197302
42 MRE11 NM_005590.3(MRE11): c.1098+614C> T single nucleotide variant other rs140067184 GRCh38 Chromosome 11, 94467199: 94467199
43 MRE11 NM_005590.3(MRE11): c.1098+614C> T single nucleotide variant other rs140067184 GRCh37 Chromosome 11, 94200365: 94200365
44 MRE11 NM_005590.3(MRE11): c.1098+1620T> C single nucleotide variant other rs397509352 GRCh38 Chromosome 11, 94466193: 94466193
45 MRE11 NM_005590.3(MRE11): c.1098+1620T> C single nucleotide variant other rs397509352 GRCh37 Chromosome 11, 94199359: 94199359
46 MRE11 NM_005590.3(MRE11): c.1098+1408A> G single nucleotide variant other rs200367125 GRCh38 Chromosome 11, 94466405: 94466405
47 MRE11 NM_005590.3(MRE11): c.*631C> T single nucleotide variant other rs397509347 GRCh38 Chromosome 11, 94419494: 94419494
48 MRE11 NM_005590.3(MRE11): c.*631C> T single nucleotide variant other rs397509347 GRCh37 Chromosome 11, 94152660: 94152660
49 MRE11 NM_005590.3(MRE11): c.*570A> C single nucleotide variant other rs397509346 GRCh38 Chromosome 11, 94419555: 94419555
50 MRE11 NM_005590.3(MRE11): c.*570A> C single nucleotide variant other rs397509346 GRCh37 Chromosome 11, 94152721: 94152721

Copy number variations for Bladder Cancer from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14770 1 110031964 110037890 Decreasing copy number GSTM1 Bladder cancer
2 16660 1 128900000 185800000 Gain Bladder cancer
3 18051 1 143699872 161705044 Gain Bladder cancer
4 36534 1 77068898 77170790 Loss Bladder cancer
5 51778 11 130615965 132678521 Loss Bladder cancer
6 53648 11 31517796 32050223 Loss Bladder cancer
7 58531 11 68323054 69297218 Gain Bladder cancer
8 67850 12 45466239 58591220 Gain Bladder cancer
9 75136 13 16000000 114142980 Copy number Bladder cancer
10 79497 13 72534137 72746128 Gain Bladder cancer
11 80757 13 97270228 100084626 Gain Bladder cancer
12 81341 14 101619009 102408085 Loss Bladder cancer
13 83177 14 19364851 19446107 Loss Bladder cancer
14 87829 14 77750645 79747731 Loss Bladder cancer
15 88246 14 88632756 89467875 Gain Bladder cancer
16 89915 15 19427350 19427409 Loss Bladder cancer
17 96847 15 95052889 95403459 Loss Bladder cancer
18 97491 16 10647794 11795463 Gain Bladder cancer
19 98997 16 22221235 32532138 Gain Bladder cancer
20 101674 16 45413780 45607724 Gain Bladder cancer
21 101856 16 46548299 69323131 Loss Bladder cancer
22 104499 16 69543004 70813070 Gain Bladder cancer
23 107647 17 1649595 1725887 Loss Bladder cancer
24 109050 17 24000000 38100000 Gain Bladder cancer
25 109225 17 24641926 27576519 Gain Bladder cancer
26 112300 17 38521264 78444637 Gain Bladder cancer
27 118108 17 7571719 7590863 Loss TP53 Bladder cancer
28 121742 18 467310 796252 Gain Bladder cancer
29 122814 18 61643142 67432063 Loss Bladder cancer
30 126424 19 18749534 19294814 Gain Bladder cancer
31 127148 19 278073 12616127 Gain Bladder cancer
32 127869 19 37856935 63485510 Gain Bladder cancer
33 135679 2 11956730 12796508 Gain Bladder cancer
34 135959 2 123437325 126399586 Loss Bladder cancer
35 138231 2 159948195 160120757 Loss Bladder cancer
36 141850 2 217249378 242464793 Loss Bladder cancer
37 146581 2 51236117 51635693 Loss Bladder cancer
38 147190 2 60966923 61033726 Loss Bladder cancer
39 147284 2 62081310 62298660 Loss Bladder cancer
40 148163 2 74469 50579433 Loss Bladder cancer
41 150320 2 9872881 10505097 Gain Bladder cancer
42 150974 20 157771 456225 Gain Bladder cancer
43 151125 20 17870221 18440898 Gain Bladder cancer
44 151502 20 22093371 26036562 Gain Bladder cancer
45 152003 20 28081598 47163674 Gain Bladder cancer
46 154726 20 48033501 54958791 Gain Bladder cancer
47 156571 20 61727753 62175139 Gain Bladder cancer
48 158507 21 33581851 34132794 Gain Bladder cancer
49 160744 22 16259597 16597551 Loss Bladder cancer
50 164078 22 34482413 35495073 Gain Bladder cancer

Expression for Bladder Cancer

Search GEO for disease gene expression data for Bladder Cancer.

Pathways for Bladder Cancer

Pathways related to Bladder Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Bladder cancer hsa05219
2 MicroRNAs in cancer hsa05206

GO Terms for Bladder Cancer

Cellular components related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MIR10B MIR127 MIR143 MIR21 MIR221

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.77 HRAS MIR21 MIR221 RB1 TSC1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 FGFR3 HRAS MIR21 MIR221
3 Ras protein signal transduction GO:0007265 9.58 HRAS KRAS RB1
4 positive regulation of protein kinase B signaling GO:0051897 9.56 FGFR3 MIR143 MIR21 MIR221
5 striated muscle cell differentiation GO:0051146 9.46 KRAS RB1
6 gene silencing by miRNA GO:0035195 9.43 H19 MIR10B MIR127 MIR143 MIR21 MIR221
7 negative regulation of GTPase activity GO:0034260 9.33 HRAS MIR21 TSC1
8 response to isolation stress GO:0035900 9.32 HRAS KRAS
9 positive regulation of vascular associated smooth muscle cell migration GO:1904754 8.8 MIR143 MIR21 MIR221

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR10B MIR143 MIR21 MIR221

Sources for Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....